All the thirteenR/R DLBCL and B-ALL patients had received the clinical trial of anti-CD19 CAR-T cell expressing anti-CD19 scFv and 4–1BB-CD3ζ costimulatory-activation domains therapy (ChiCTR-ONN-16009862) in our hospital. The leukapheresis was done when they were enrolled in this anti-CD19-CAR T cell therapy clinical trial. Then the procedures for cell production and quality-control assays were conducted according to our literature before.14 All the patients received lymphodepleting chemotherapy with fludarabine (30 mg/m2) and cyclophosphamide (400 mg/m2) from day −4 to day −2. Autologous anti-CD19-CAR T cells were infused on day 0 in R/R DLBCL and B-ALL patients (2x106 cells/kg).

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.